Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 19/20 | 0.80 |
| ▸ | SLC6A3 | Q01959 | 19/20 | 0.80 |
| ▸ | SLC6A4 | P31645 | 18/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1503336 | 1.00 | SLC6A2 (0.80) | SLC6A2SLC6A3SLC6A4 | |
| Liafensine SCHEMBL1120125 | 0.89 | SLC6A2 (1.00) | SLC6A2SLC6A3SLC6A4 | |
| Liafensine SCHEMBL1120067 | 0.89 | SLC6A2 (1.00) | SLC6A2SLC6A3SLC6A4 | |
| Liafensine SCHEMBL12573238 | 0.89 | SLC6A2 (1.00) | SLC6A2SLC6A3SLC6A4 | |
| Liafensine SCHEMBL29376965 | 0.89 | SLC6A2 (1.00) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL17461972 | 0.89 | SLC6A2 (0.81) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL4306960 | 0.89 | SLC6A2 (0.81) | SLC6A2SLC6A3SLC6A4 | |
| Liafensine SCHEMBL1119993 | 0.88 | SLC6A2 (0.98) | SLC6A2SLC6A3SLC6A4 | |
| Liafensine SCHEMBL1119990 | 0.88 | SLC6A2 (0.98) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL1120342 | 0.88 | SLC6A2 (0.80) | SLC6A2SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150191494-A1 | TETRAHYDROISOQUINOLINES AND INTERMEDIATES THEREFOR | ALBANY MOLECULAR RESEARCH, INC. | 2015-07-09 | — | — | US | disclosed |
| US-8420811-B2 | Tetrahydroisoquinolines and intermediates therefor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-16 | — | — | US | disclosed |
| US-20130060027-A1 | TETRAHYDROISOQUINOLINES AND INTERMEDIATES THEREFOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-07 | — | — | US | disclosed |
| US-20110077400-A1 | PROCESSES FOR PREPARING TETRAHYDROISOQUINOLINES | Bristol-Myers Squibb Company and Albany Molecular Research, Inc | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130060027-A1 | TETRAHYDROISOQUINOLINES AND INTERMEDIATES THEREFOR | FARS2, TPH1, COQ8A | SLC6A2 254/4885SLC6A3 459/4885SLC6A4 104/4885 |
| US-20150191494-A1 | TETRAHYDROISOQUINOLINES AND INTERMEDIATES THEREFOR | FARS2, TPH1, COQ8A | SLC6A2 254/4885SLC6A3 459/4885SLC6A4 104/4885 |
| US-20110077400-A1 | PROCESSES FOR PREPARING TETRAHYDROISOQUINOLINES | HTR2C, HTR3B, TPH2 | SLC6A2 217/4885SLC6A3 503/4885SLC6A4 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.